With Kiwa Biotech products being deployed in established sales networks in China by experienced players and a plan for production expansion of the higher margin core microbial product, we need to hear on what the new sales guidance attributed to KWBT will be in the cooperation to give KWBT shareholders some targets above the 2019 base case of $40million, in addition to the promised release of the 3 quarters of financials. Plenty to digest.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.